HomeNDC LookupDrug shortages › Somatropin Injection

Somatropin Injection shortage

Somatropin Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Endocrinology/Metabolism 1 product 312 days First posted Nov 14, 2025 Updated Nov 14, 2025
Here’s the bottom line

Novo Nordisk is stopping its somatropin injection 30 mg/3 mL, and this change may be permanent. Other somatropin products, including Norditropin (somatropin) in several strengths, are still listed as available from makers that have not reported a shortage.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
312
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Somatropin Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
To be discontinued 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Somatropin Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Novo Nordisk Sandoz Inc
Plus 5 alternative dosage forms of Somatropin.
See all other options & details →
Shortage timeline
  1. Nov 14, 2025
    Currently in shortage
    1 of 1 product affected.
  2. Nov 14, 2025
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Novo Nordisk, Inc. 📞 833-493-4689 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) NDC 00169-7703-21 Discontinuation of the manufacture of the drug

These rows are manufacturer reports to the FDA for Somatropin Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Somatropin Injection? options further down this page.

Why is Somatropin Injection in shortage?

Novo Nordisk has let the FDA know that they are permanently stopping the manufacturing of their Norditropin somatropin injection in the 30 mg/3 mL size (the specific package with NDC 0169-7703-21). That's why this particular product is on the shortage list.

It's worth knowing that Novo Nordisk did not share a more detailed public reason for why they made this decision — just that manufacturing of this specific size is being discontinued. This applies only to that one strength and package size from Novo Nordisk, and only reflects what this one manufacturer reported to the FDA.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Somatropin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Somatropin Injection?

Somatropin injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.

The strength affected is the 30 mg/3 mL pen (Norditropin), reported by Novo Nordisk. This strength has no available source right now, and the reason given is that the manufacturer is discontinuing production. Because this is listed as "to be discontinued," this particular product's supply problem may be permanent rather than a short-term gap. That makes a conversation with your prescriber the right next step so you can plan ahead.

Please do not let this alarm you — somatropin is still made in other strengths and by another company, and your care team has good options to keep your treatment steady.

Here is what I suggest, in order:

  1. Do not stop, skip, or change your dose on your own.
  2. Since your exact strength is being discontinued, ask your prescriber or pharmacist about options — for example, a different Norditropin strength (such as 5, 10, or 15 mg/1.5 mL) or Omnitrope (5 or 10 mg/1.5 mL), which are the same medicine from Novo Nordisk or Sandoz.
  3. Your pharmacy may be able to source one of these, though it may not be in local stock.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is general, national information and may not match your local pharmacy's actual supply.

See “Where else can I get Somatropin Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Somatropin guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Somatropin guide →

Where else can I get Somatropin Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Somatropin Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Norditropin SOMATROPIN 30 mg/3mL Injection, Solution · Subcutaneous Novo Nordisk 00169-7703-92
Norditropin SOMATROPIN 5 mg/1.5mL Injection, Solution · Subcutaneous Novo Nordisk 00169-7704-21
Norditropin SOMATROPIN 10 mg/1.5mL Injection, Solution · Subcutaneous Novo Nordisk 00169-7705-21
Norditropin SOMATROPIN 15 mg/1.5mL Injection, Solution · Subcutaneous Novo Nordisk 00169-7708-21
Omnitrope SOMATROPIN 5 mg/1.5mL Injection, Solution · Subcutaneous Sandoz Inc 00781-3001-07
Omnitrope SOMATROPIN 10 mg/1.5mL Injection, Solution · Subcutaneous Sandoz Inc 00781-3004-07

Alternative dosage forms of Somatropin

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 1 productclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Norditropin 30 mg/3mLNDC 00169-7703-21 Novo 1 syringe FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Somatropin Injection — that fall in the same broad treatment class (growth hormones) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 065287
GCN 25816
HICL code 002824
Ingredient (HICL) Somatropin
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P1
Therapeutic class — intermediate (HIC2) Anteriorpituitary Hormones
HIC3 code P1A
Therapeutic class — specific (HIC3) Growth Hormones
AHFS code 68:28.00.00
AHFS class Pituitary
FDB label name NORDITROPIN FLEXPRO 30 MG/3 ML
FDB brand name Norditropin Flexpro
Legend status F — Federal legend — prescription drug or device
GPI-143010002000D260
GPI classNorditropin FlexPro
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other endocrinology/metabolism shortages

Somatropin Injection shortage FAQs

Is Somatropin Injection in shortage?
Yes — the FDA currently lists Somatropin Injection in shortage (status: “To Be Discontinued”, first reported Nov 14, 2025). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) (NDC 00169-7703-21). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Somatropin Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Somatropin somewhere?
Other manufacturers (Novo Nordisk, Sandoz Inc) still market it and have not reported a shortage. 5 alternative dosage forms of Somatropin are also listed. See “Where else can I get Somatropin Injection?” above — stock still varies by pharmacy.
What should I do if I take Somatropin Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Somatropin Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages